The ascendency of total ankle arthroplasty (TAA) over the past several decades, from a niche procedure to the gold-standard treatment for ankle arthritis, has been remarkable to watch. Although total ankle replacement was initially viewed with suspicion regarding its design, durability, and functionality, a newly trained orthopaedic foot and ankle surgeon enters practice employing TAA as a safe, effective, and first-line treatment 1,2 . This new regime has been built on the efforts of skilled clinicians and inquisitive researchers from around the world and is an accomplishment for which we, as a community, should all take pride.As clinicians, we are constantly reminded that with success must come failure, and that dichotomy holds true for TAA. The failure of a joint replacement is a considerable emotional and economic burden for patients and a similar burden for both surgeons and health systems. The failure rate, defined as implant revision or conversion to arthrodesis, can be as high as 10% in the first 5 years and can approach 20% at ‡10 years 3,4 . As is true with all retrospective assessments, the results may not reflect the current state of the art with respect to technique, technology, and outcomes, but prudence and humility would not have us dismiss the results of such studies out of hand, as they serve as benchmarks for ongoing improvement.In their present study, Jamjoom et al. detail the revision of 29 failed TAA cases with the INBONE II prosthesis, a fixedbearing implant with intramedullary tibial fixation and cross-linked polyethylene. The results were generally excellent and on par with primary procedures, with implant survival of 97%, albeit at a follow-up of just over 3 years 1,2 . The authors deserve particular recognition for their prospective collection of patient-reported outcome measures, the Manchester-Oxford Foot Questionnaire (MOXFQ) and EuroQol-5 Dimensions (EQ-5D), which demonstrated progressive functional improvement up to 24 months postoperatively. Complications were remarkably low, with just 1 nerve injury and 1 postoperative infection treated with debridement and implant retention. A concern is the 28% rate of talar component subsidence of ‡5 mm at the latest followup, which will require ongoing scrutiny.The available literature on the revision of TAA is sparse and, where available, includes small numbers and limited follow-up. Behrens et al. reported on a series of 18 patients who underwent revision with the INBONE prosthesis; survival was 78% at 4 years, but the results may have been affected by the high rate of preoperative osteolysis 5 . Egglestone et al., also utilizing the INBONE prosthesis, revised 21 failed total ankle replacements, with 87% 4-year survival and improved patient-reported outcome measures at 2 years 6 . Finally, Lachman et al. evaluated 52 TAA cases requiring implant revision, utilizing the INBONE I or II implants in nearly 80% of patients, with 3 years of follow-up and a 21% failure rate; the patient-reported outcome measures for the patients who underwent revis...